IgA nephropathy, also known as Berger’s disease, is a kidney disorder that occurs when IgA antibody gets settled in kidneys. The disease is an auto immune disorder caused due to the accumulation of the IgA which results in inflammation and further damages the glomeruli in kidney. The causes of IgA nephropathy are still not very clear, but it is an immune response to foreign particles such as bacteria or virus. The immune response releases IgA antibody, a protein that fight against infections in the body. In certain cases, the disease develops in patients with a family history of IgA nephropathy. Researchers also believe that genetic factors also play a key role as a cause of the disease.
IgA nephropathy is a silent disease and shows no symptoms in its early stage. The most common symptoms that are usually observed are proteinuria (leakage of protein in urine) and hematuria (leakage of blood in urine).
Some other signs and symptoms of the IgA nephropathy are nausea, high blood pressure, dry skin, feeling tired, reduced urination, weight loss, loss of appetite and sleeping problems. Diagnosis of IgA nephropathy can be done by tests including physical examination, blood test, urine test and kidney biopsy. Various promising targets and unavailability of specific treatment driving the growth of pipeline therapeutics of IgA nephropathy.
As of March 2018, the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development.
IGA NEPHROPATHY THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2018)
IGA NEPHROPATHY- NUMBER OF PREVALENT CASES IN 7MM (2016)
Some of the key players developing drugs for the treatment of IgA nephropathy include Mallinckrodt plc, Merck KGaA, Novartis AG, and Shire plc.